<unk>  acts on the prostacyclin receptor of lung tissue. It is selective for the prostacyclin receptor. The binding of<unk>  to this receptor leads to three major effects: increased vasodilation of the arteries, decreased cell proliferation and inhibition of platelet aggregation, all beneficial in the treatment of pulmonary arterial hypertension.
Selexipag
Vosoritide
Vagisil
Prasugrel
Eteplirsen
Furegrelate
Snoezelen
Tezacaftor